TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Evidence of HIV infection confirmed by positive culture or PCR on at least two occasions, or a positive ELISA and a confirmatory Western Blot. At least one of these tests must be done in an ACTG certified laboratory which is approved to perform the assay for protocol testing~* Age 4-21 years~* Current use of HAART regimen (NRTI or/and NNRTI based) containing a PI~* HIV-RNA levels above 1,000 copies/mL (Stage II)~* vIQ\<1 for Kaletra~* Signed informed consent and, if indicated, signed informed assent or waiver of assent.~Exclusion criteria:~* Grade 3-4 DAIDS defined toxicity~* Use of cimetidine (used as the internal standard for the HPLC-MS/MS assay)~* Any active opportunistic infection~* Any of the following laboratory findings at entry: absolute neutrophil count \<750 cells/mm3; platelet count \<75,000 cells/mm3; AST \>3 times upper limit of age adjusted normal values; ALT \>3 times upper limit of age adjusted normal values; serum creatinine \>1.2mg/dL.~* Patients on dual PI regimen (except when second PI is given for boosting) at the time of enrollment

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Therapeutic Dose Adjustment (Type: None): To adjust the doses of medications to meet target therapeutic concentrations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Ilioinguinal Single-shot and Three-layer Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II children aged 0-16 presenting for inguinal surgery (inguinal hernia, hydrocele repair, or orchidopexy)~Exclusion Criteria:~* Patient or parent refusal to participate in study, local anesthetic allergy, or any other contraindication to ilio-inguinal nerve block.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Study group: 3-layer block (Type: EXPERIMENTAL): Patients in this group will receive the 3-layer ilioinguinal nerve block.
- Control: single-shot block (Type: ACTIVE_COMPARATOR): Patients in this group will receive a standard, single-shot ilioinguinal nerve block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase (Fasturtec) Registration Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At high risk of malignancy and/or chemotherapy-induced hyperuricemia~* Performance status less than 3 on ECOG scale or more than 30% KPS scale~* Uric acid concentrations ≥ 8.0mg/dL~* Suffering from non-Hodgkin's lymphoma Stage more than III, or acute lymphoblastic leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma or leukemia~Exclusion Criteria:~* Treatment with an investigational drug at any time during the 14-day study period (except for agents that are permitted by the Sponsor)~* Pregnancy or lactation~* Prior treatment with Uricozyme or Rasburicase~* Scheduled to receive asparaginase either 24 hours after the first dose of rasburicase~* Treatment with Allopurinol within the seven days preceding study Day 1~* History of significant atopic allergy problems or documented history of asthma~* History of severe reaction to allopurinol~* Known history of glucose-6-phosphate dehydrogenase deficiency.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): IV infusion at a dose level of 0.20mg/kg per day
- 2 (Type: ACTIVE_COMPARATOR): 100mg tablets, administered orally, according to standard medical practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial for the Treatment of Relapsed Osteosarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of high grade osteosarcoma recurrence~* Resectable or unresectable recurrence disease within 24 months from the initial diagnosis~* Pleuro-pulmonary recurrence with more than 2 nodules within 24 months from the initial diagnosis~* Unresectable first relapse within 24 months from the initial diagnosis~* Resectable or unresectable second of further recurrence of high grade osteosarcoma~* Age at diagnosis at least 4years.~* Karnofsky performance status over 60%.~* Renal function and hepatic In normal limits for age.~* L eft ejection ventricular fraction over 50%.~* White blood cells over 3000 million/liter and platelets 100000 million/liter~* Birth potential female must agreed to contraception~* Signed written informed consent~Exclusion Criteria:~* Contraindication to the use of any study drugs~* Mental, social and geographic conditions which fail to ensure adequate adherence to the study~* Hepatitis and human immunodeficiency virus active infection~* Pregnancy or breast-feeding~* Previous treatment with Gemcitabine, Docetaxel and Ifosfamide

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine and Docetaxel (Type: EXPERIMENTAL): Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
- Ifosfamide (Type: EXPERIMENTAL): Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of skin, gut and/or liver steroid-refractory GVHD by clinical assessment of treating physician following allogeneic HCT. Patients who fail to respond to steroids by 7 days are considered steroid-refractory~2. Previously-treated with any conditioning regimen and any GVHD immune suppression prophylaxis and formulation of steroids, except as noted in Exclusion Criteria #2.~3. AbGn-168H (neihulizumab) therapy can begin not more than 14 days after diagnosis of aGvHD~4. Karnofsky Performance Status (KPS) \> 50%~5. No evidence of HCT graft failure or multi-organ failure~6. Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~1. Uncontrolled infections not responsive to antimicrobial therapy requiring intensive critical care~2. Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy~3. Treatment with investigational GVHD prophylactic agents (eg, CCR5 inhibitors; lenalidomide; and/or bortezomib) within the 7 days prior to the 1st dose of neihulizumab~4. Treatment with other investigational agents within the prior 7 days prior to the 1st dose of AbGn-168H (neihulizumab)~5. CMV PCR \> 500 copies/mL or evidence of end-organ damage due to CMV~6. Pregnant or nursing~7. HIV positivity (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case-by-case basis)~8. Renal clearance CCR \< 40 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AbGn-168H (Type: EXPERIMENTAL): AbGn-168H will be administered once weekly for four weeks via intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient must require amputation on a limb secondary to PAD, defined as arterial insufficiency due to atherosclerosis based on one or more of the following assessments:~  * Ankle brachial index;~ * Duplex ultrasonography showing clinically significant occlusion;~ * Arteriography; or~ * Assessment demonstrating stenosis by arterial calcification.~* Able to give informed consent,~* Be at least 18 years of age.~Exclusion Criteria:~* No history of major amputation on the affected limb, or~* Life expectancy less than 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of end stage renal disease~Exclusion Criteria:~* History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus erythematosis, presence of transcutaneous access (external catheter)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept 25 mg (Type: ACTIVE_COMPARATOR): Etanercept 25 mg injection twice a week
- Saline (Type: PLACEBO_COMPARATOR): Saline injection twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fotemustine in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic malignant melanoma, meeting the following criteria:~  * Metastatic lymph nodes or skin allowing for surgical resection~ * At least 1 metastatic lesion (lymph nodes, skin, visceral, brain)~* Measurable or evaluable disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* ANC \> 2 x 10\^9/L~* Platelet count \> 100 x 10\^9/L~* Transaminases ≤ 2.5 times normal~* Alkaline phosphate ≤ 2.5 times normal~* Total bilirubin normal~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No severe uncontrolled infection~* No other prior or concurrent malignancy (except basal cell or squamous cell carcinoma in situ of the cervix that was curatively treated)~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* At least 2 weeks since prior adjuvant therapy~* At least 4 weeks since prior radiotherapy~* At least 30 days since prior participation in another clinical trial~* No prior or concurrent prophylactic phenytoin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Evaluation of PUSPENs and C&Cs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets Diagnostic and Statistical Manual-IV criteria for opioid dependence~* Physically and psychologically capable of understanding and undergoing informed consent process~* Within 90 days of release or discharge and intending to return to Klang Valley region~* For VTC arm, came to the C\&C to start MMT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Compulsory Drug Detention Center (Type: None): Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
- Voluntary Treatment Center (Type: None): Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or second primary squamous cell head and neck cancer~* Defined area of recurrence on imaging~* Previous head and neck radiation (RT) to \>/= 50 Gy~* Performance status score 0-1~* Time interval from previous RT \>/= 9 months~* Volume of disease appropriate for protocol treatment~* Minimum estimated survival of \>/= 3 months~* Age \>/= 18~* Adequate labs~Exclusion Criteria:~* Primary tumors of the salivary gland~* Original pathology report and radiation therapy records not available~* Prior spinal cord dose \> 45 Gy~* Surgery or chemotherapy within 4 weeks~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers are permitted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel + Stereotactic Radiation (Type: EXPERIMENTAL): Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by \> 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Topical Benzocaine for Analgesia in Lingual Frenotomy of the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Full term Newborn infant~* Tongue-tie upon physical examination~* Maternal complains of nipple pain or difficult latch~Exclusion Criteria:~* Abnormal oral or nasopharyngeal anatomy~* Any known congenital malformations~* Prematurity

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 7 Days
- Healthy Volunteers: t

Study Arms:
- Topical Benzocaine (Type: ACTIVE_COMPARATOR): For infants treated with topical benzocaine prior to the procedure
- no benzocaine (Type: NO_INTERVENTION): No benzocaine applied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Endomicroscopy in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be available before any trial-related procedures~* Male and female patients aged 18 years and older~* Clinically and histologically verified UC~* Duration or Colitis ulcerosa \>8 years (date of first diagnosis)~* Colitis Activity Index ≤ 8~* Activity index of Truelove and Witts: mild~* Ability of subject to understand character and individual consequences of clinical trial~* For women with childbearing potential, adequate contraception.~Exclusion Criteria:~* Known intraepithelial neoplasia or colorectal cancer~* Coagulopathy (Prothrombin time \<50% of control, Partial thromboplastin time \>50 s)~* Impaired renal function (Creatinine \>1.2 mg/dL)~* Pregnancy or breast feeding~* Inability to obtain informed consent~* Active GI Bleeding~* Known allergy to methylene blue or fluorescein~* Participation in other clinical trials within the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Chromoscopy-guided endomicroscopy with targeted biopsies
- B (Type: ACTIVE_COMPARATOR): Standard endoscopy with random and targeted biopsies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam Treatment of Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Neonatal seizure occurred and was proved by EEG according to abnormal discharge of brain. one or more of the following :~1. Male or female term baby with gestational \>37 weeks and postnatal age \< or= 28 days~2. Birthweight \>2500g~3. Written informed consent of parent or guardian~Exclusion Criteria:~1. Babies who have been close to death~2. Seizure occurred by metabolic factors (hypoglycemia, hypocalcemia, electrolyte disorder)~3. Babies who have received phenobarbitone or any other anticonvulsive medication before hospitalization~4. Abnormal renal function

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Oral levetiracetam (Type: EXPERIMENTAL): Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
- Intravenous phenobarbital (Type: ACTIVE_COMPARATOR): Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Consent to biopsy at start and end of therapy~* Suspicion of Lichen sclerosus~* Pre-menopausal~* Age ≥18 years~Exclusion Criteria~* Prior surgery at the vulva, with exception of episiotomy~* Pregnancy~* Signs of infection with human papilloma virus at the vulva~* Vulvar intraepithelial neoplasia (VIN)~* Known generalised autoimmune disease~* Lichen sclerosus since childhood~* Prior therapy with topic clobetasol propionate or other immunosuppressives (tacrolimus or pimecrolimus) at the vulva~* Atopic diathesis and/or contact allergy~* Systemic immunosuppressive therapy~* Genital infection within the last four weeks (eg., condyloma acuminata, candidiasis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
- 2 (Type: EXPERIMENTAL): Progesterone 8%, topical application, once daily about 2 g, during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cooled Versus Conventional Genicular Radiofrequency Ablation for Chronic Knee Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female (above age of 18)~* Diagnosed with chronic knee osteoarthritis or post Total Knee Arthroscopy or post Total Knee Replacement Pain~* More than 3 months of knee pain~* Scheduled for Genicular Knee ablation (Cooled or conventional ablation)~* Had previous intra articular injection (steroids or Hyaluronic acids) if not a post-surgical knee pain patient~* Achieved minimum 50% relief from genicular block x 2~* Numeric Rating Scale Score of 4 or greater~* Kellgren-Lawrence Knee Osteoarthritis Grade 2 or greater (in non post-surgical patients)~Exclusion Criteria:~* Pregnant adult female~* Patient fully anticoagulated~* Antiplatelet Use~* History of Clotting Disorder~* Refusal to participate~* Focal neurologic deficits~* Cognitive deficits~* History of Bone Cancer~* Mental Health Illness which causes instability~* Previous Knee radiofrequency ablation~* Active Infection~* Allergy to Medications Administered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Genicular Ablation (Type: None): This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
- Cooled radiofrequency Ablation (Type: None): This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility